We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
In April 2017, the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) for Eli Lilly and Company and Incyte Corporation’s baricitinib for moderate-to-severe rheumatoid arthritis (RA).